These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121 [TBL] [Abstract][Full Text] [Related]
8. Management of inflammatory choroidal neovascularization (CNV) secondary to punctate inner choroidopathy in a young female of childbearing age with intra-vitreal ranibizumab and half-fluence photodynamic therapy (PDT) - a holistic approach. Cornish KS; Lim LT; Imrie F Semin Ophthalmol; 2012; 27(1-2):29-32. PubMed ID: 22352824 [TBL] [Abstract][Full Text] [Related]
12. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. Varano M; Tedeschi M; Oddone F; Perillo L; Coppè AM; Parravano M Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453 [TBL] [Abstract][Full Text] [Related]
13. Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy. Menezo V; Cuthbertson F; Downes SM Retina; 2010 Oct; 30(9):1400-4. PubMed ID: 20224465 [TBL] [Abstract][Full Text] [Related]
14. Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab. Ehlken C; Martin G; Stahl A; Agostini HT Arch Ophthalmol; 2012 Sep; 130(9):1226-7. PubMed ID: 22965611 [No Abstract] [Full Text] [Related]